We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

EUROPEAN COMMISSION PUBLISHES REPORT ON EXTERNAL REFERENCE PRICING FOR MEDICINAL PRODUCTS

Ciara Farrell

18 March 2014
On 10 March 2014, the European Commission ("Commission") published a report which details the results of an assessment of external reference pricing on pricing and reimbursement decisions for medicinal products in the European Union ("EU").  The report was produced and funded under the EU Health Programme 2008-2013.

The report identifies the main parameters which impact the pricing and reimbursement decisions for medicinal products within external reference pricing systems.  These parameters include the effects of pricing and reimbursement decisions for medicinal products taken in one EU Member State on pricing and reimbursement decisions in other EU Member States.

Based on a simulation model, the assessment identified these main parameters in all 28 EU Member States.  The report also briefly examines the external reference pricing processes in non-EU countries such as Australia, Canada, Japan and Turkey.


 

Ciara Farrell

EMA to Revise Herbal Medicines Guideline

On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...

08 September 2016
Loading data